[23, 24] In clinical practice, the mTOR inhibitors have also been approved for the treatment of advanced renal cell carcinoma, pancreatic neuroendocrine tumors, and hormone receptor-positive breast cancer [25]. The gene discussed is MTOR; the disease is hereditary clear cell renal cell carcinoma.